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Abstract To explore the functional role of TIMP-2 in liver, we 
determined TIMP-2 mRNA levels in primary rat hepatocytes and 
in total rat liver. Rat hepatocytes constitutively express TIMP-2 
mRNA at a low level. Incubation with dexamethasone, prosta- 
glandin E2 and a combination of inflammatory cytokines leads to 
an up-regulation of TIMP-2 mRNA. In rats in vivo we found a 
dramatic increase of TIMP-2 expression after intraperitoneal 
injection of lipopolysaccharide. Compared to our previous find- 
ings on TIMP-1 we conclude that TIMP-2 mRNA expression is 
regulated in a distinct and partially opposite manner. Over-pro- 
duction of TIMP-2 could inhibit the activity of metallopro- 
teinases and thus lead to matrix accumulation. Dysregulation of 
TIMP-2 synthesis might be involved in the development of liver 
fibrosis. 
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1. Introduction 
Tissue inhibitor of metalloproteinases-2 (TIMP-2) is a 21 
kDa protein which forms a non-covalent complex with a 1 : 1 
stoichiometry with the latent and active matrix metallopro- 
teinase type IV collagenase and the 92 kDa gelatinase [1-4]. The 
N-terminal amino acid sequence of the protein is more than 
60% identical to a consensus sequence of mammalian TIMP-1 
[5]. TIMP-2 shares several properties with TIMP-1, including 
conservation of the positions of the 12 cysteine residues and 
resistance to cleavage by trypsin. 
TIMP-2 is secreted by melanoma cells [1], fibrosarcoma cells 
[6], lung fibroblasts [7], human alveolar macrophages [8], 
human osteoblast-like c lls [9], human vein and microvascular 
endothelial cells [10] and found in human plasma [11] as well 
as in the majority of 26 human tumor cell lines [12]. TIMP-2 
was purified from human rheumatoid synovial f uid and serum- 
free medium of a human hepatoma cell line HLE [2,13]. Inter- 
estingly TIMP-2 levels in the sera of patients with rheumatoid 
arthritis and hepatocellular carcinomas were significantly 
higher than those of normal subjects [14]. Northern blot analy- 
sis of RNA from human melanoma or fibrosarcoma cell lines, 
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normal and tumor tissue samples demonstrated two distinct 
transcripts of 1.0 and 3.5 kb for TIMP-2 mRNA. Both tran- 
scripts are down-regulated in response to transforming growth 
factor-,8 and remain unchanged in response to PMA [6]. in 
most other human cell lines, TIMP-2 expression was refractory 
to IL-1, PMA and TNF-~ treatment [15]. In human alveolar 
macrophages treatment with LPS, denatured type I collagen 
and zymosan resulted in a dose-dependent and profound de- 
crease of TIMP-2 production [8]. In rabbit uterine cervical 
fibroblasts, progesterone increased the production of TIMP-2 
[16]. In contrast the expression of TIMP-I mRNA is induced 
by serum, PMA, fibroblast growth factor and platelet-derived 
growth factor [17-19]. Oncostatin M, interleukin-6 (IL-6), leu- 
kemia inhibitory factor, and IL-I~ elevate TIMP-1 expression 
at the mRNA level in human lung fibroblasts [20]. Thus, TIMP- 
1 and TIMP-2 transcription is differentially regulated in vivo 
and in vitro in cell culture, indicating a different physiologic 
role for the two TIMPs [21,22]. 
In a previous report we have demonstrated that TIMP-I is 
up-regulated by inflammatory c tokines in rat hepatocyte pri- 
mary cultures and we discussed a possible involvement of 
TIMP-1 in the pathogenesis of liver fibrosis [23,24]. Here we 
show for the first time that TIMP-2 expression is up-regulated 
by cytokines and prostaglandin E2 in primary rat hepatocytes 
and by LPS in rat liver. Furthermore we demonstrate hat 
TIMP-1 and TIMP-2 are differently regulated genes in liver 
cells. 
2. Materials and methods 
2.1. Materials 
The random primed DNA labeling kit was purchased from Boehrin- 
ger-Mannheim (Mannheim, Germany). [~-32p]dATP (110 TBq/mmol) 
was obtained from Amersham International (Amersham, UK). M199 
and FCS were from Gibco (Eggenstein, Germany); Escherichia coli 
LPS, PGE2 were from Sigma (Munich, Germany). Recombinant 
human (rh) IL-lfl with a specific activity of 2 x 107 units/mg protein was 
a generous gift of Dr. A.R. Shaw (Glaxo Institute for Molecular Biol- 
ogy, Geneva, Switzerland). rh IL-6 with a specific activity of 1.5 x 10 ~' 
B-cell stimulatory factor 2 units/mg protein was generously supplied by 
Drs. T. Hirano and T. Kishimoto (Osaka, Japan). rh IL-I1 with a 
specific activity of 2.5 x 10 6 units/mg protein in a TI0 cell bioassay was 
obtained from Genetics Institute (Boston, MA). The cloning of murine 
TIMP-1 [25] and TIMP-2 [21] has recently been described. 
2.2. Preparation of hepatocyte primary cultures 
After perfusion of rat livers with collagenase, rat hepatocytes were 
prepared as described in[23,26]. Hepatocytes were cultured serum-free 
for 48 h prior to the experiments. 
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2.3. Animal experiments 
Male Sprague-Dawley rats weighing 220-250 g were injected in- 
traperitoneally with 2.3 mg of LPS. 0, 2 and 24 h after injection, rats 
were sacrificed, the livers were excised, immediately frozen in liquid 
nitrogen and stored at -80°C for subsequent analysis. For Northern 
blotting at each time point tissues were analyzed individually. Animal 
studies were performed in accordance with required standards of the 
local animal welfare committee. 
2.4. RNA isolation and Northern analysis 
Total RNA was isolated from liver tissues and from rat hepatocytes 
in primary culture as described in [27]. 5/lg of RNA were heated to 
65°C for 10 rain in 50% formamide, 20 mmol/l 3-[N-mor- 
pholino]propane sulfonic acid (MOPS), 5 mmol/l sodium acetate, 
1 mmol/l EDTA and 2.2 mol/l formaldehyde b fore gel-electrophoresis 
in 1% agarose containing 2.2 mol/1 formaldehyde, 20 mmol/l MOPS, 
5 mmol/l sodium acetate and 1 mmol/l EDTA. Equal loading of the 
RNA gel was checked by ethidium bromide staining of 18 S and 28 S 
ribosomal RNA. The separated RNA was transferred to GeneScreen 
Plus membranes (DuPont-De-Nemours, Dreieich, Germany) according 
to the supplier's instructions. The filters were prehybridized at 68°C for 
2 h in 10% dextran sulfate, 1 moll1 sodium chloride and 1% SDS and 
hybridized in the same solution with cDNA fragments labeled by ran- 
dom priming [28]. After hybridization, unspecifically bound radioactiv- 
ity was removed by washing in 2 x standard saline citrate solution (SSC) 
at room temperature, followed by two consecutive washes in 2 x SSC, 
1% SDS at 68°C for 30 min each. The filters were then subjected to 
autoradiography with intensifying screens at -80°C. Autoradiograms 
from at least three separate xperiments were analyzed. 
3. Results 
Total RNA isolated from the murine cell lines B78 and NIH 
3T3, total rat liver, primary rat hepatocytes and the rat 
hepatoma cell line H35 was analyzed for TIMP-2 mRNA ex- 
pression (Fig. 1). In comparison to a high expression in the 
murine melanoma cells B78, rat liver cells displayed low TIMP- 
2 mRNA levels. When rat hepatocytes were incubated with 
conditioned medium from LPS-stimulated human monocytes, 
known to contain many different inflammatory mediators, a
dramatic increase of TIMP-2 mRNA was observed (Fig. 2). 
Among different agents tested, dexamethasone, prostaglandin 
E 2 (in low concentrations) and also conditioned medium from 
unstimulated human monocytes enhanced the expression of 
TIMP-2 mRNA, whereas fetal calf serum had no effect. When 
rat hepatocytes were stimulated with conditioned medium of 
LPS-treated human monocytes, the lower TIMP-2 transcript 
showed a slightly higher mobility (Fig. 2). Inflammatory cyto- 
kines alone had no marked effect on the expression of TIMP-2 
mRNA, but the combinations of IL-lfl + IL-6 or IL-lfl + IL- 
6 + IL-11 led to a synergistic up-regulation ofT IMP-2 mRNA 
expression (Fig. 3). Surprisingly only the 1.0 kb TIMP-2 tran- 
script increased upon incubation with the combination of cy- 
tokines. 
To analyze the expression of TIMP-2 in vivo we injected rats 
intraperitoneally with LPS. 2 and 24 h after LPS administration 
total hepatic RNA was prepared and subjected to Northern 
blot analysis. Fig. 4A illustrates the induction of TIMP-2 
mRNA expression by LPS in comparison to control animals 
injected with NaC1. Similar to our observation in cell culture 
when rat hepatocytes were incubated with conditioned medium 
of LPS-stimulated human monocytes, we found an additional 
smaller transcript of TIMP-2 after 24 h. Interestingly, we also 
observed a TIMP-1 transcript of higher mobility after LPS 
treatment in vivo (Fig. 4B). 
4. Discussion 
The present study shows for the first time that rat hepato- 
cytes in primary culture and total rat liver in vivo express 
TIMP-2 mRNA. Furthermore, we could demonstrate an up- 
regulation of TIMP-2 mRNA by conditioned medium of LPS- 
stimulated human monocytes, by a combination of inflamma- 
tory cytokines, by prostaglandin E 2 or by dexamethasone. In 
primary rat hepatocytes TIMP-2 expression is unaffected by 
fetal calf serum (Fig. 2), ciliary neurotrophic factor and leuke- 
mia inhibitory factor (data not shown) or by a stimulation with 
IL-lfl, IL-6 or IL-I 1 alone (Fig. 3). 
In a previous report we demonstrated that rat hepatocytes 
in primary culture constitutively express TIMP-1 mRNA at a 
low level. Incubation with conditioned medium from LPS-stim- 
ulated human monocytes led to a dramatic increase of TIMP-1 
mRNA. The inflammatory cytokines IL-lfl, IL-6, IL-1I and 
CNTF were also capable of stimulating TIMP-I  mRNA in a 
dose- and time-dependent manner. Among these cytokines IL-6 
was the most potent stimulator. A combination of IL-lfl, IL-6 
and IL-11 synergistically increased mRNA levels of TIMP-1. 
On the other hand the synthetic glucocorticoid examethasone 
inhibited basal and IL-6-induced expression of TIMP-1 dose- 
dependently. 
The regulation of TIMP-2 expression in rat hepatocytes by 
dexamethasone and inflammatory cytokines, however, differs 
from that of TIMP-1. Like others [22] we propose different 
(refering to the dexamethason effect and the effect of single 
inflammatory cytokines) but also similar (refering to the effect 
of conditioned medium and a combination of cytokines) mech- 
anisms regulating TIMP-1 and TIMP-2 expression, indicating 
both different and also partly similar physiological roles for the 
two TIMPs. The closely related regulation of TIMP-1 and 
TIMP-2 might be of importance for the fine tuning of the 
homeostasis of the extracellular matrix. 
The balance between activated metalloproteinases and avail- 
able inhibitors is thought o be a critical determinant of matrix 
protein turnover associated with a variety of pathologic proc- 
esses, including tumor cell invasion and fibrosis [29 32]. TIMP- 
2 is considered as a potential tumor terminator [33]. Addition 
of endogenous TIMP-2 protein blocks tumor invasion of 
human fibrosarcoma HT-1080 cells [34]. Transfection of inva- 
sive metastatic rat cells with TIMP-2 resulted in reduced local 
invasion and partially suppressed hematogenous metastasis 
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Fig. 1. Expression of TIMP-2 in different murine and rat cells. Total 
RNA was isolated and 5/Jg were used for Northern blot analysis of 
TIMP-2 mRNA. 
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Fig. 2. Effect of dexamethasone, f tal calf serum, prostaglandin E2 and conditioned medium from LPS-stimulated human monocytes on TIMP-2 
levels in rat hepatocyte primary cultures. Rat hepatocytes (4x 106 cells per dish) were incubated in the presence of 10 -7 moll1 dexamethasone, 10% 
and 30% fetal calf serum (FCS), 1 ml of conditioned medium (CM) from LPS-stimulated human monocytes (1/tg/ml for 18 h) and prostaglandin 
E2 (PGE2) in different concentrations (10 -7, 10 -6 and 10 -5 mol/l). Total RNA was isolated and 5 ,ug were used for Northern blot analysis of TIMP-2 
mRNA. When the T1MP-2 cDNA probe was used an unspecific ross hybridization to 28 S ribosomal RNA was observed, which served as an internal 
standard. 
[35]. Independent of its proteinase inhibitory activity TIMP-2 
is able to inhibit cultured endothelial cell proliferation, which 
suggests additional actions limiting neovascularization associ- 
ated with solid tumor growth and metastasis [36]. Expression 
of TIMP-1 and TIMP-2 correlates with the development of 
glomerulosclerosis. Both T IMP genes are expressed in normal 
glomeruli, and their expression is increased in glomerulosclero- 
sis associated with renal carcinoma [29]. Furthermore, en- 
dogenous TIMPs play a central role in regulating both physio- 
logical and pathological bone resorption [37]. 
Fibrosis is characterized by an accumulation of extracellular 
proteins, which might be the result of an increase in their syn- 
thesis or a decrease in degradation or a combination of both. 
Our results provide evidence that in hepatocytes, besides 
TIMP-1, TIMP-2 may also be involved in the regulation of 
extracellular matrix protein metabolism. A high TIMP-2 activ- 
ity would reduce metalloproteinase activity and thus result in 
matrix accumulation by an impairment of matrix degradation. 
Our data also suggest hat TIMP-2, like TIMP-1 [23], might be 
involved in liver fibrosis. Additional support for this conclusion 
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Fig. 3. TIMP-2 mRNA stimulation by a combination of cytokines. Rat hepatocytes in primary culture were incubated for 8 h in the presence of 10 7 
moll1 dexamethasone and combinations ofIL-6 (100 U/ml), IL-lfl (100 U/ml) and IL-11 (100 U/ml) as indicated in the figure. Total RNA was extracted 
and 5/lg were analyzed by Northern blotting. When the TIMP-2 cDNA probe was used, an unspecific ross-hybridization to 28 S ribosomal RNA 
was observed, which served as an internal standard. 
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Fig. 4. Expression of TIMP-2 in vivo. Rats were injected intraperitone- 
ally with LPS. 2 and 24 h after LPS administration, RNA from total 
rat liver was analyzed by Northern blotting. (A) Hybridization with a 
murine TIMP-2 cDNA. (B) Hybridization with a murine TIMP-I 
probe. 
is derived from some recent clinical studies. TIMP-2 levels in 
sera of patients with hepatocellular carcinoma were signifi- 
cantly higher than those of normal subjects [14]. The level of 
TIMP-2 expression was increased in glomerulosclerosis associ- 
ated with renal carcinoma [29]. Serum TIMP-1 levels were 
closely correlated with the histological degree of liver fibrosis 
in chronic liver diseases, such as chronic persistent and chronic 
active hepatitis, liver cirrhosis, primary biliary cirrhosis and 
hepatocellular carcinoma [38]. Further studies with experimen- 
tal models of liver fibrosis and biopsy samples from patients 
with chronic liver disease are required to establish a functional 
relationship between the observed changes in T IMP expression 
and hepatic fibrosis. To define the role of the different T IMP 
proteins in liver fibrosis, studies with transgenic or knock-out 
animals for TIMP-1/TIMP-2 have to be performed. 
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